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Summary
Background—Oral emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) pre-exposure 
prophylaxis (PrEP) is used to prevent the sexual acquisition of HIV. Transgender women (TGW) 
have unique characteristics that may relate to PrEP use, effectiveness, and safety.
Methods—The iPrEx trial was a randomized controlled trial (RCT) of oral FTC/TDF PrEP 
versus placebo among men who have sex with men (MSM) and TGW, followed by an open label 
extension (OLE). Drug concentrations were measured in blood by liquid chromatography and 
tandem mass spectroscopy.
Findings—Of the 2499 participants enrolled in the RCT, 29 (1%) identified as women, 296 
(12%) identified as “trans”, 14 (1%) identified as men but reported use of feminizing hormones, 
such that 339 (14%) reported one or more of these characteristics (TGW). Compared with MSM, 
TGW more frequently reported transactional sex, receptive anal intercourse without a condom, or 
more than 5 partners in the past 3 months. Among TGW, there were 11 HIV infections in the 
active arm and 10 in the placebo arm, representing a hazard ratio of 1.1 (95% CI: 0.5 to 2.7). 
Among active arm participants, drug was detected in none of the TGW at the seroconversion visit, 
18% (6/37) of seronegative TGW (P=0.31), and 52% (58/111) of seronegative MSM (P < 0.0001). 
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PrEP use was not linked to behavioral indicators of HIV risk among TGW, while MSM at highest 
risk were more adherent.
Interpretation—There were no HIV infections among TGW having drug concentrations 
commensurate with use of 4 or more FTC/TDF tablets per week. TGW receiving PrEP had low 
drug concentrations, especially at times of potential HIV exposure, leading to no PrEP 
effectiveness among this subgroup.
Funding—U.S. National Institutes of Health and the Bill and Melinda Gates Foundation; study 
medication was donated by Gilead Sciences.
Introduction
Transgender refers to a person whose gender identity differs from their assigned birth sex 
(1). While regional and national data on transgender populations are not available, a recent 
statewide Massachusetts telephone survey found that 0.5% of respondents identified as 
transgender (2). Due to incomplete or inconsistent collection of gender identity data (such as 
birth sex and current gender identity), transgender people’s participation in research is 
frequently obscured (3, 4).
The prevalence of human immunodeficiency (HIV) infection is high in transgender 
communities (5); A 2008 meta-analysis of 22 U.S. regional studies (that did report HIV 
infection rates for TGW) found an HIV infection prevalence of 27.7% based on laboratory 
confirmation, and 11.8% based on self-report (6). In 2011, the US Centers for Disease 
Control (CDC) reported that TGW have the highest HIV-1 incidence (incidence of 2.1%, 
compared to 1.2% among non-transgender men and 0.4% among non-transgender women) 
(7). A 2013 meta-analysis of data from 15 countries found an estimated HIV prevalence of 
19.1% among transgender women, with an odds ratio of 49 in comparison to the general 
adult population (5).
Transgender women frequently face structural barriers, including inadequate legal 
protections against discrimination, and resulting insecurities in income, food, and housing, 
that contribute to the disproportionate burden of HIV among TGW (8, 9). TGW have had 
limited engagement in PrEP research that has been primarily focused on MSM (10). 
Research and services adapted for transgender populations includes staff training and 
procedures for ensuring gender affirmation and provision of gender affirming hormone 
therapy.
There are no evidence-based HIV prevention interventions designed specifically for TGW. 
PrEP acceptability studies among MSM and TGW have typically included few TGW, with 
no consideration for the sociocultural (and perhaps anatomical) differences between these 
two dissimilar communities (11, 12). Guidelines may assume similar practices and efficacies 
in MSM and transgender populations. For example, World Health Organization (WHO) 
guidelines provide no specific considerations for the provision of PrEP to TGW (13). United 
States Centers for Disease Control (CDC) guidelines for PrEP implementation make no 
mention of TGW (14). PrEP demonstration projects to date have reported low or unclear 
levels of enrollment of TGW (15).
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This report describes the subgroup of TGW in iPrEx with respect to PrEP efficacy, 
effectiveness, PrEP drug concentrations, and patterns of adherence in the TGW subgroup.
Methods
Study Design
The iPrEx trial was a randomized, double-blind, placebo-controlled Phase III clinical trial of 
oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention of once daily oral 
FTC/TDF PrEP conducted between 2007 and 2011 in Brazil, Ecuador, Peru, South Africa, 
Thailand, and the United States (16). The randomized clinical trial (RCT) was followed by 
an open label extension (OLE) between 2011 and 2013 (17).
Participants
Inclusion and exclusion criteria for the iPrEx trial have been reported in detail previously 
(16). People assigned male sex at birth were eligible for the iPrEx study, regardless of their 
current gender identity. Current gender identity was self-reported using a computer assisted 
self-interview (CASI), which asked whether the participant currently identified as a man or a 
woman (trans was not given as an option). A second CASI question asked “How do you 
identify yourself?” and included “trans” and “woman” among other options in a “check all 
that apply” format. The word “travesti” was used in Ecuador as the word “trans” was not in 
common use. Use of feminizing hormones, including the use of hormones obtained without 
a prescription, was assessed and recorded as concomitant medications at every visit by 
medical history, and was coded using the Uppsala Monitoring Centre WHO Drug Dictionary 
Enhanced (Sweden). Information about gender affirming surgeries was extracted from the 
medical record. Feminizing hormones were defined as any estrogen, progestagen, or anti-
androgen. Finasteride was not included as a TGW-defining characteristic, as this medication 
was primarily used for androgenic alopecia rather than feminization. Except as noted, the 
“TGW” subgroup is defined as participants who were assigned male sex at birth and who 
currently identify as women (regardless of trans identification), or who identified as trans 
(regardless of self-reported gender), or who used feminizing hormones (regardless of 
reported gender or trans status). In analyses stratified by feminizing hormone use, and in the 
analysis of PrEP drug detection by sexual HIV risk, we refer to trans/women (vs MSM) 
based only on reported gender identity regardless of hormone use.
Outcomes
Testing for emtricitabine and tenofovir and their active metabolites was performed by liquid 
chromatography and tandem mass spectroscopy as previously described.(17, 18) All 
available plasma and peripheral blood mononuclear cells (PBMC) in iPrEx RCT and OLE 
were tested in the active arm seroconverters as well as controls who remained seronegative. 
Testing of drug in iPrEx OLE additionally measured active drug metabolites in dried blood 
spots (DBS).(17, 19)
Procedures
Enrolled participants were followed for HIV seroconversion and adverse events at weeks 4, 
8, 12, and every 12 weeks thereafter in the RCT and OLE. There was an additional 
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scheduled visit at week 16 in the RCT. DBS was collected only in OLE. Hormone therapy 
was not provided to study participants by any of the study sites.
Randomisation and Masking—During the iPrEx RCT, enrolled participants were 
randomly assigned 1:1 to daily oral FTC/TDF vs a matching placebo in randomized blocks 
of 20. During iPrEx OLE, all eligible participants were offered oral FTC/TDF PrEP and 
were followed for HIV seroconversion regardless of PrEP uptake.
Statistical Analysis
A separate analysis of MSM and TGW was not planned. Testing of pharmacology 
specimens in the RCT was conducted among participants randomized to FTC/TDF who 
became HIV+ during the study (cases) who were each matched (by site and week in the 
study) to HIV− participant (controls). Testing of specimens in OLE used a case-cohort 
design (20) which tested all available specimens longitudinal in patients electing to take 
PrEP who became HIV+ (cases) and a randomly selected (stratified by site) HIV− cohort. 
Using the case-cohort, the probability of selection for testing was known by the design of 
our case cohort study. The reciprocal of the probability of selection was incorporated as a 
probability weight in the OLE analyses of the risk HIV acquisition by drug level using 
Poisson regression which permits estimation of average rates, estimated person years and 
rate ratios. Analyses comparing the relative rate of HIV by levels of TFV-DP (Figure 2 and 
Table 3) in MSM and TG participants adjusted for potential confounders of the association 
of TFV-DP with HIV acquisition: report of non-condom receptive anal intercourse, age, 
number of partners and diagnosis of syphilis.
Comparison of HIV acquisition between FTC/TDF and placebo for HIV infection in the 
RCT used a stratified (by site) Cox proportional hazards model. The proportional hazards 
assumption was verified by Schoenfeld test. The p-value for the Schoenfeld test of 
proportional hazard was P=0.45, suggesting the proportional hazard assumptions was 
approximately satisfied. Comparisons in bone mineral density and creatinine values used the 
t-test with unequal variances. Normal quantile plots suggested the normal assumptions were 
approximately satisfied. Very similar results were obtained using the Mann-Whitney U-test. 
Comparison of proportions between groups were adjusted for study site by logistic 
regression with the relevant group and study site as the factors in the logistic regression 
otherwise specified. Logistic regression model fits were verified by the methods of Hosmer 
and Lemeshow. All p-values were two sided.
Role of the Funding Source
As sponsor the iPrEx RCT and OLE, the NIH reviewed and approved the study protocol and 
study manuals. The Bill and Melinda Gates Foundation and Gilead Sciences had no role in 
protocol development or the interpretation of results. The sponsor and funders of the study 
had no role in data collection, data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the study and had final responsibility 
for the decision to submit for publication.
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Results
In the RCT, among 2,499 enrolled participants across all 11 sites, 296 (12%) participants 
identified as transgender and 29 (1%) participants identified as a woman. An additional 14 
(1%) male-identified participants reported exogenous female hormone use of some kind. 
The total number of participants from each of these three categories aggregated into the 
TGW group was 339 (14%). The distribution of TGW participants as well as sub-identities 
within this group did not differ between the intervention and placebo arms. Study sites in the 
Andes and Thailand recruited a larger proportion of TGW, and the majority of TGW overall 
in the study (Table 1).
In the iPrEx RCT, use of feminizing hormones was reported by 67/339 (20%) of TGW; 48 
of 296 (16%) trans-identified participants, 5 of 29 (17%) women participants, and 14/2160 
(0.6%) of participants who did not identify as either trans or women. Among 163 feminizing 
regimens reported by 67 participants, 60 (37%) contained synthetic estrogens, 58 (35%) 
contained natural estrogens, 121 (74%) contained progestogens, and 38 (23%) contained 
antiandrogens, either alone or in combination with other hormones.
There were multiple demographic and behavioral differences between TGW and MSM 
(Table 2). TGW were younger (p=0.010) on average, although there was no difference in age 
after controlling for study site (P=0.43). TGW had less schooling (p<0.0001), more sexual 
partners (p<0.0001), less condom use for receptive anal sex (p<0.0001), more reported STIs 
(p<0.0001), more cocaine or methamphetamines use (p<0.0001), and were more likely to 
live alone (p<0.0001) and have a history of transactional sex (p<0.0001).
In iPrEx OLE, 192 TGW enrolled and were eligible for PrEP, of whom 151 (79%) chose to 
take PrEP for at least part of the study period; PrEP uptake was 76% (1074/1409) among 
MSM and was comparable to TGW (p=0.96).
Among seronegative participants in iPrEx OLE receiving PrEP, TGW had lower PrEP drug 
concentrations compared with MSM overall, regardless of hormone use as reported 
previously (17). TGW had less time with protective drug concentrations compared with 
MSM (33/200 person years or 17% vs 464/1332 person years or 35%, P < 0.0001, Table 3), 
while having comparable time with any drug detected (142/200 person years or 71% vs 
1006/1332 person years or 76%, P=0.17, Table 3), especially at week 4 after starting PrEP 
(93% [33/35] vs 93% [251/274], P=0.99, Fig 1a).
Among participants not reporting feminizing hormone use, a similar proportion of trans/
women and MSM had drug detected at any concentration over time (OR = 1.27, 95% CI = 
0.83 to 1.93, p = 0.29) while also in this group of non-hormone users there was a trend 
toward lower proportions of trans/women having protective drug concentrations indicating 
use of 4+ tablets per week (OR = 0.71, 95% CI = 0.49 to 1.03, p=0.07). Trans/women who 
reported use of feminizing hormones were less likely to have any drug detected (Fig. 1a) or 
protective drug concentrations (Fig. 1b) compared with trans/women not using hormones 
(OR = 0.32, 95% CI = 0.16 to 0.66, p = 0.002 for any drug detection; OR = 0.14, 95% CI 
0.05 to 0.41, p < 0.0001 for protective concentrations) and compared with MSM who were 
not using hormones (OR = 0.41, 95% CI = 0.23 to 0.74, p =0.003, for any drug detection; 
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OR = 0.10, 95% CI 0.04 to 0.28, p < 0.0001, for protective concentrations). There were no 
differences in drug concentrations comparing trans/women using synthetic estrogens versus 
trans/women using natural estrogens (P=0.74). None of the trans/women using progestogens 
were included in the cohort selected for drug concentration analysis.
In the RCT, compared with MSM of any hormone status, PrEP drug testing among trans/
women (regardless of hormone use) revealed less consistent PrEP use (always vs less than 
always, OR=0.39, 95% CI 0.16 to 0.96, P=0.04, Fig. 3). Among all MSM regardless of 
hormone use, those who reported non-condom receptive anal intercourse were more likely to 
use PrEP compared with those who reported consistent condom use or no anal intercourse 
(never vs any, OR=2.5, 95% CI 1.4 to 4.2, P < 0.0005 ), while trans and women of any 
hormone status reporting this risk factor tended to be less likely to use PrEP (never vs any, 
OR = 0.38, 95% CI 0.04 to 3.6, P= 0.40). There was a trend toward an interaction between 
gender in the relationship between risk and PrEP use (P=0.12).
In the modified intention-to-treat analysis of the RCT (excluding only participants who were 
already HIV infected when they started PrEP), 11 TGW participants in the intervention 
group seroconverted as compared to 10 in the placebo group (HR 1.1, 95% CI 0.5 to 2.7; 
p=0.77 for effectiveness in TGW). This hazard ratio among TGW tended to be higher, 
reflecting lower effectiveness, than was observed among MSM (HR 0.50, 95% 0.34 to 0.75; 
P=0.001 for effectiveness in MSM; p=0.09 for the difference in PrEP effectiveness between 
TGW and MSM. Two TGW seroconverted after receiving PrEP in iPrEx OLE, and one in 
the group that elected not to use PrEP.
Among TGW seroconverterters in iPrEx RCT, none (0 of 11) had drug detected in blood 
plasma or PBMC at the time of infection, compared with 6 of 33 (18%) of seronegative 
TGW (p=0.31). Among TGW, the HIV incidence was 0 (95% CI not calculable) if drug was 
detected, and 4.9/100py (95% CI 3.0 to 7.7) if drug was not detected. Among MSM, the 
HIV incidence was 0.4/100PY (95% CI 0 to 0.8) if drug was detected, and 2.8/100py (95% 
CI 1.8 to 3.7) if drug was not detected.
Among TGW seroconverters in iPrEx OLE, one had DBS levels below the limits of 
quantitation and 1 had drug concentrations that indicated average use of fewer than 2 PrEP 
tablets per week. The relationship between drug concentration in DBS and HIV incidence 
was comparable among MSM and TGW (Table 3, Figure 2). As with MSM, there were no 
HIV infections among TGW having drug concentrations commensurate with use of 4 or 
more tablets per week (HR 0, 95% CI 0 to 10.1). Drug concentrations commensurate with 
use of 2 to 3 tablets per week were present in 12% (24/200 py) of follow-up of TGW, and 
there were no infections that group as well (HR 0, 95% CI 0 to 13.0).
Among TGW, moderate and severe adverse events (AEs) were rare, and there was no 
difference comparing the active and placebo arms (31 vs. 28 events, P=0.73). There were 2 
deaths among TGW: one in the placebo arm was due to homicide and another in the active 
arm was due to acute liver failure probably due to lymphoma that occurred after at least 336 
days of no detectable PrEP drugs in blood plasma or PBMC. There was a non-significant 
mean difference from baseline in estimated creatinine clearance at week 24 of −1.0 ml/min 
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(95% CI: −3.8 to +1.8, P=0.48) in the active arm, which was similar to differences in MSM.
(21) Bone mineral density (BMD) at the hip changed +0.5% (95% CI: −0.5 to +1.5 from 
baseline in TGW at week 24, compared with −0.4% (95% CI: −0.7 to −0.2) among MSM 
(P=0.08 for the difference between MSM and TGW), and at the spine, BMD changed +0.3 
(95% CI: −0.8 to +1.3) from baseline in TGW and −0.7% (95% CI: −0.3 to −1.2) among 
MSM (P=0.08 for the difference between MSM and TGW). Liver function abnormalities 
occurred at comparable rates in the active versus the placebo arms among TGW (4 [6/170] 
vs. 3% [5/169], P=0.90).
Discussion
PrEP use in transgender populations is protective in the setting of drug adherence; none of 
the TGW who became infected in the RCT had detectable drug at the time of seroconversion 
in the randomized phase. Furthermore, quantitative analysis of long-term drug exposure, 
afforded by use of DBS in iPrEx OLE, revealed that seroconversion occurred only among 
TGW having drug concentrations commensurate with using less than 2 tablets of FTC/TDF 
per week on average. The lack of protection appears to be due primarily to low adherence 
leading to low drug exposure, as measured by drug concentrations.
To be effective, medications used for PrEP must be at a protective concentration at the time 
of exposure to HIV infection. TGW in iPrEx who reported sexual practices conferring the 
highest risk of HIV infection tended to be less likely to have PrEP drug detected in blood 
(Fig. 3). This is of particular concern given that TGW reported greater overall exposure to 
HIV (more partners, less condom use, more sexually transmitted infections) and had lower 
overall adherence. In contrast, the positive associations observed between PrEP adherence 
and indicators of sexual risk among MSM likely account for why PrEP effectiveness was 
commensurate with drug exposure in that group.
Considerations unique to TGW could undermine PrEP use (22). The lack of PrEP 
effectiveness on an intention-to-treat basis among TGW, and low levels of PrEP drug 
exposure, are similar to findings from two PrEP trials in non-transgender women that 
showed no effectiveness and very low levels of PrEP drug exposure (23, 24). These trials 
also found a negative association between behavioral factors associated with HIV incidence 
and detection of drug levels (24, 25), as we have found for TGW. Linkage between HIV 
exposure and PrEP use is important for PrEP impact, and could have contributed to the 
effectiveness of PrEP among MSM despite moderate PrEP use observed here.
There were lower TDF-DP concentrations in DBS among TGW using feminizing hormones 
compared with other TGW. This may reflect less PrEP adherence among TGW whose 
concerns about drug-drug interactions that were not fully addressed during the trial. FTC 
and TDF are cleared in the kidney while estrogens and progestogens are metabolized in the 
liver, so no systemic drug-drug interactions are expected. TDF has been found to have no 
interactions with a coformulated oral contraceptive (OCP) consisting of ethinyl estradiol and 
norgestimate (27), and PrEP use does not appear to diminish contraceptive efficacy of 
hormonal medications (28). Furthermore, oral TDF or FTC/TDF PrEP efficacy has been 
shown to not be diminished by depot medroxyprogesterone acetate (29). Analysis by 
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progestogen use was not performed in the current study as none of the subjects who reported 
only progestogen use (without estrogens) had DBS levels obtained.
No pharmacological interaction studies have been done in TGW using both PrEP and gender 
affirming feminizing hormones, which differ from contraceptives in several respects. For 
example, in order to achieve consistent ovulation suppression oral contraceptives contain the 
synthetic estrogen ethinyl estradiol, while most recommended regimens for feminization 
utilize 17-beta estradiol (30). Potent anti-androgens, such as spironolactone, may be 
included in feminizing hormone therapy but is not used in contraceptives. Future study of 
potential interactions between PrEP and feminizing hormone regimensshould include drug 
transporters that are affected by both nucleoside analogues and female sex hormones and 
could affect PrEP drug concentrations in cells infected by HIV (31, 32).
Interactions between exogenous female sex hormones and HIV susceptibility are also 
important for PrEP protection, which can be overcome if viral exposure efficiently leads to 
transmission during gaps in PrEP use. While estrogens preserve pelvic tissues, including 
anal epithelium, and reduce viral susceptibility in an animal model (reviewed in(33)), 
medroxyprogesterone acetate may decrease vaginal thickness and increase HIV 
susceptibility in non-transgender women (34). How this effect translates to the anal 
epithelium is unknown. To the extent that feminizing hormone regimens typically utilize 
estrogens in place of or in addition to progestogens, these hormonal effects might decrease 
HIV susceptibility overall.
TGW often prioritize hormone use over other health concerns, and some HIV-positive TGW 
report hesitance to use antiretroviral medications out of a fear of negative interactions 
between PrEP and hormones (35, 36). Information about drug-drug interactions was not 
provided routinely to TGW in this study, as little information was available and no such 
interactions were predicted. PrEP programs aimed at TGW should include education 
strategies on what is known about the coadministration of these two treatments. Monitoring 
the clinical outcomes of feminizing hormone therapy within PrEP services would provide 
additional assurance and information to TGW using PrEP. As has been seen in the arena of 
HIV treatment, negative experiences with clinics and providers unsupportive of transgender 
identities or not fluent in transgender culture (either in the past or in a current PrEP 
program) may make transgender women less likely to engage in PrEP programs or use PrEP 
when provided.(22, 37)
The primary limitation of this subgroup analysis is that the study was not designed to detect 
differences in effectiveness among TGW and MSM, or to confirm efficacy in either 
subgroup. The other primary limitation arises from difficulties encountered in identifying 
TGW. This challenge was compounded by reliance on hormone use data collected by self-
report, and by the inclusion of participants defined by a range of terminology, languages and 
cultures spanning four continents. While best practices for collection of gender identity have 
been described for populations in the United States (4), future study of global populations 
should engage local communities to inform gender identity collection methods to be used in 
each cultural and linguistic setting. This study identified multiple differences between MSM 
and TGW and sexual practices and PrEP use; there may be unmeasured or unknown factors 
Deutsch et al. Page 8
Lancet HIV. Author manuscript; available in PMC 2016 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
that explain these differences. Retention in iPrEx was comparably high among TGW and 
MSM (84% and 85% respectively), and the main risk factor for HIV acquisition in both 
groups was receptive anal intercourse without a condom.
PrEP is a proven method of HIV prevention that is controlled by the receptive partner, 
whether a non-transgender woman, a receptive MSM, or a receptive TGW. Best practices for 
PrEP services among TGW could arise from gender-affirming clinical settings that integrate 
PrEP with hormone therapy and other sexual health services. Studies of PrEP use in TGW 
populations should be designed and tailored specifically for this population, rather than 
adapted from or subsumed into studies of MSM.
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Figure 1. 
Tenofovir Diphosphate (TFV-DP) in dried blood spots (DBS) in iPrEx OLE over duration of 
PrEP use by gender and use of feminizing hormones. Gender and hormone use were 
assessed at enrollment. A) depicts the proportion of participants with any TFV-DP detection 
vs below limit of quantitation (BLQ), representing approximately 1 or more tablets taken in 
the past 4 weeks. B) depicts the proportion of participants with TFV-DP greater than 700 
fmol/punch, which was associated with 100% protection regardless of identity or hormone 
use.
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Figure 2. 
HIV rate ratios for HIV infection by TFV-DP levels detected in blood in iPrEx OLE by 
gender. Drug concentrations from MSM (blue) and TGW (purple) were testing used PBMCs 
collected on the visit at seroconversion. HR is relative to visits among a randomly selected 
participants on PrEP, matched by gender, who remained seronegative and had TFV-DP levels 
below the limits of quantation (BLQ). The exponential regression curve is solid and the 95% 
CI is dotted. There was no difference between the groups (P=0.85).
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Figure 3. 
Proportion of participants by consistency of drug detection, gender, and non-condom 
receptive anal intercourse (ncRAI). Only participants with 3 or more measurements of TFV-
DP over time are included. “Never” represents no detection of TFV-DP at any visit, “Some” 
is detection at more than one but less than all visits, and “Always” is detection at all visits.
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Table 1
Breakdown of TGW participants among HIV negative participants in iPrEx RCT by study region.
Region All TWG (%) Trans-identified (%) Women (%) Male identified but using feminizing hormones (%)
Andes (N=1700) 247 (15%) 221 (13%) 18 (1%) 8 (0%)
Brazil (N=370) 38 (10%) 30 (8%) 4 (1%) 4 (1%)
USA (N=227) 6 (3%) 5 (2%) 0 (0%) 1 (0%)
South Africa (N=88) 5 (6%) 4 (5%) 1 (1%) 0 (0%)
Thailand (N=114) 43 (38%) 36 (32%) 6 (5%) 1 (1%)
Total (N=2499) 339 (14%) 296 (12%) 29 (1%) 14 (1%)
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Table 2
Demographics of MSM v. TGW in the iPrEx Randomized Trial.
Variable Value
TGW
N=339
MSM
N=2160 P-value*
Age (mean) 26.2 27.3 P = 0.43
Education Less than HS 126 (37%) 397 (19%) P < 0.0001
High School 169 (50%) 1209 (57%)
College 42 (13%) 527 (25%)
Partners (baseline) <=1 14 (4%) 198 (9%) P < 0.0001
>1–5 82 (24%) 803 (37%)
>5–10 50 (15%) 476 (22%)
>10 193 (57%) 683 (32%)
Condomless receptive anal intercourse (ncRAI) No 49 (14%) 965 (45%) P < 0.0001
Yes 290 (86%) 1195 (55%)
Cocaine or methamphetamine use No 302 (89%) 2020 (94%) P < 0.0001
Yes 37 (11%) 140 (7%)
STI (past 6 mos) No 212 (63%) 1635 (76%) P < 0.0001
Yes 127 (38%) 525 (24%)
Circumcised No 323 (96%) 1835 (85%) P = 0.003
Yes 13 (4%) 320 (15%)
Living Situation With Partner 27 (8%) 154 (7%) P < 0.0001
Alone 77 (23%) 306 (14%)
With family/friends 230 (68%) 1663 (77%)
Other 5 (2%) 37 (2%)
Transactional Sex No 122 (36%) 1350 (63%) P < 0.0001
Yes 217 (64%) 810 (38%)
*
P-values were adjusted for study site.
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